MEIP Stock Overview
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer.
MEI Pharma, Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.54|
|52 Week High||US$3.55|
|52 Week Low||US$0.41|
|1 Month Change||-4.76%|
|3 Month Change||16.04%|
|1 Year Change||-79.47%|
|3 Year Change||-67.81%|
|5 Year Change||-78.92%|
|Change since IPO||-99.88%|
Recent News & Updates
|MEIP||US Biotechs||US Market|
Return vs Industry: MEIP underperformed the US Biotechs industry which returned -19.6% over the past year.
Return vs Market: MEIP underperformed the US Market which returned -9.6% over the past year.
|MEIP Average Weekly Movement||11.6%|
|Biotechs Industry Average Movement||12.5%|
|Market Average Movement||7.6%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.1%|
Stable Share Price: MEIP is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 12% a week.
Volatility Over Time: MEIP's weekly volatility (12%) has been stable over the past year.
About the Company
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome.
MEI Pharma, Inc. Fundamentals Summary
|MEIP fundamental statistics|
Is MEIP overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|MEIP income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.35|
|Net Profit Margin||-127.31%|
How did MEIP perform over the long term?See historical performance and comparison